Chad Bartel
Family Medicine · Arlington, TXNPI 1720472970
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 35.8% of the total. Reporting peaked in 2024 at $498 and has fallen 56.5% since, to $217 in 2025.
Across 107 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$627
- Novo Nordisk$181
- GSK$115
- Lilly USA, LLC$106
- Abbott$101
- Amgen$89
- plus $536 from 16 others
What the payments were for
- Food & beverage$1,754100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $627 |
| Novo Nordisk | 11 | $181 |
| GSK | 6 | $115 |
| Lilly USA, LLC | 7 | $106 |
| Abbott | 5 | $101 |
| Amgen | 5 | $89 |
| Pfizer | 4 | $80 |
| Astellas Pharma US Inc | 4 | $73 |
| AstraZeneca | 4 | $63 |
| Boehringer Ingelheim | 3 | $54 |
| Sanofi Pasteur Inc. | 3 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Seqirus USA Inc | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Gilead | 1 | $19 |
| Merck | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$1,754 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 48 | $77,042 |
| JardianceEmpagliflozin | 35 | $46,361 |
| EliquisApixaban | 33 | $35,077 |
| RybelsusSemaglutide | 16 | $34,386 |
| OzempicSemaglutide | 22 | $31,569 |
| TradjentaLinagliptin | 22 | $21,433 |
| JanuviaSitagliptin Phosphate | 18 | $18,973 |
| Testosterone | 15 | $3,844 |
| Trazodone Hcl | 75 | $3,364 |
| Atorvastatin Calcium | 254 | $2,100 |
| Levothyroxine Sodium | 193 | $1,634 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 22 | $1,336 |
| Omeprazole | 71 | $1,319 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,318 |
| Rosuvastatin Calcium | 150 | $1,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $106 | $77,04248 claims |
| Boehringer IngelheimJardiance, Tradjenta | $54 | $67,79457 claims |
| Novo NordiskRybelsus, Ozempic | $181 | $65,95538 claims |
| PfizerEliquis | $80 | $35,07733 claims |
| MerckJanuvia | $18 | $18,97318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Arlington
- Bradley WassonArlington$734K
- Gilbert LedesmaArlington$34K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.